In this issue:
Belzutifan for RCC in von Hippel-Lindau disease
Definitive radiotherapy for oligometastatic RCC
Cabozantinib for brain metastases in patients with RCC
Cytoreductive nephrectomy in mRCC
Genetic risk assessment for hereditary RCC
Germline variants in early-onset RCC
Treatment-free survival after ICI for advanced RCC
High-dose interleukin-2 and stereotactic ablative radiotherapy for mRCC
Blood flow predicts long-term antiangiogenic outcomes in mRCC
Ibrutinib and nivolumab for advanced refractory RCC
Please login below to download this issue (PDF)